Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Graft-vs-Host Disease Clinical Trial

Official title:
A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease

Status Active, not recruiting

Clinical Trial Summary

The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD). Patients diagnosed with GVHD who have not responded satisfactorily to, or are intolerant of, treatment with standard agents will be considered for entry. Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial. The research is being conducted at up to 20 clinical research sites in the US.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00032279
Study type	Interventional
Source	Facet Biotech
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00031148` - Keratinocyte Growth Factor to Prevent Acute GVHD	Phase 1/Phase 2
Terminated	`NCT01940796` - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)	Phase 1
Terminated	`NCT00548717` - Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT01318330` - Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)	Phase 1
Terminated	`NCT01994824` - Preemptive Therapy of GVHD	Phase 2
Completed	`NCT01512498` - Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche
Completed	`NCT00189748` - A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-	Phase 2
Completed	`NCT02409134` - Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat
Completed	`NCT00189761` - A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients	Phase 2